New research has revealed potential, new strategies to fight against P. aeruginosa infection and improve both survival and quality of life in patients with cystic fibrosis. The study, entitled “Normal and Cystic Fibrosis Human Bronchial Epithelial Cells Infected with Pseudomonas aeruginosa Exhibit Distinct Gene Activation Patterns” was published in the …
News
Contrary to previous research, in a recent study published in the journal BMC Pulmonary Medicine, scientists did not find any general elevated risk for anxiety and depression among patients with Cystic Fibrosis. In people with CF, a defective gene causes a thick buildup of mucus…
A new study revealed that adaptive changes in Pseudomonas aeruginosa may exacerbate pulmonary inflammation and contribute to the pathogenesis and progression of chronic lung disease in the context of cystic fibrosis. The study entitled “Cystic fibrosis–adapted Pseudomonas aeruginosa quorum sensing lasR mutants cause hyperinflammatory responses” was published in July in the Science Advances journal.
A new study entitled “A novel siderophore system is essential for the growth of Pseudomonas aeruginosa in airway mucus” published in the Scientific Reports journal by researchers from the PLUS Project for Medical Science and Yonsei University College of Medicine in Seoul, Korea, identified a genetic element that codifies…
The British non-profit organization Cystic Fibrosis Trust has launched a survey entitled “Cystic Fibrosis & Treatment – What Matters to You?” for patients to share their thoughts and needs regarding treatment for cystic fibrosis (CF). With the motto “Use your voice to support access to transformational treatments,”…
Galapagos NV, a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action for treating diseases such as cystic fibrosis as well as inflammation and other indications, recently announced that its drug candidate GLPG2665 has been chosen to be developed as a next-generation…
Researchers from the University of Queensland (UQ), Australia, have recently released findings from their scientific literature review in an effort to identify all cases of Burkholderia pseudomallei infections in cystic fibrosis (CF) patients globally, the potential risk factors for acquisition, clinical consequences, and optimal treatment strategies. The findings entitled, “An international,…
Exciting new research, partly funded by the U.K. Cystic Fibrosis Trust and the Robert Luff Foundation and announced at the Trust’s U.K. CF Conference last week, shows promising results in reconditioning poorly functioning donor lungs and reducing acute organ rejection in a trial on pigs, the Trust reports. A…
Vertex Pharmaceuticals Incorporated is a global biotechnology company whose corporate mission is to discover, develop and commercialize innovative medicines that can help people with serious diseases lead better lives. Vertex initiated its CF research program in 1998 as part of a collaboration with Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT),…
Proteostasis Therapeutics, Inc. (PTI), a company that develops disease-modifying therapeutics for diseases involving protein processing, recently announced at a presentation during the 29th Annual North American Cystic Fibrosis Conference data on its transmembrane conductance regulator (CFTR) amplifier program for use in combined treatments for patients with cystic fibrosis (CF). In…
Your CF Community
Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.